Labopharm Inc. is an international specialty pharmaceutical company focused on improving existing drugs by incorporating its advanced controlled-release technologies. The Company develops products internally in order to enter into strategic alliances or licensing agreements with national or international pharmaceutical companies that have the necessary resources and distribution networks to market and sell its pharmaceutical products. The Company’s wholly owned subsidiaries include Labopharm Europe Limited, Labopharm (Barbados) Limited, Labopharm Cyprus Limited and Labopharm USA, Inc. The global commercialization program for its lead product, a once-daily formulation of the analgesic tramadol, is underway and it has multiple follow-on products in the later stages of development. Its once-daily tramadol product has been launched in 15 countries.